4.8 Article

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis

期刊

CELL METABOLISM
卷 32, 期 3, 页码 437-+

出版社

CELL PRESS
DOI: 10.1016/j.cmet.2020.07.007

关键词

-

资金

  1. Sao Paulo Research Foundation -FAPESP [2015/15626-8, 2016/23328-0, 2016/18031-8, 2018/22505-0, 20/04579-7, 2020/04746-0, 2019/06372-3, 2020/04558-0, 2020/04919-2, 2020/04583-4, 2017/01184-9, 2020/04522-5, 2019/00098-7]
  2. Fundo de Apoio ao Ensino, Pesquisa e Extensao (FAEPEX), Unicamp [2274/20]
  3. Brazilian National Council for Scientific and Technological Development - CNPq
  4. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES) [001]
  5. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [20/04579-7] Funding Source: FAPESP

向作者/读者索取更多资源

COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals with uncontrolled glucose levels are more prone to develop the severe form of COVID-19. The molecular mechanism underlying SARS-CoV-2 infection and what determines the onset of the cytokine storm found in severe COVID-19 patients are unknown. Monocytes and macrophages are the most enriched immune cell types in the lungs of COVID-19 patients and appear to have a central role in the pathogenicity of the disease. These cells adapt their metabolism upon infection and become highly glycolytic, which facilitates SARS-CoV-2 replication. The infection triggers mitochondrial ROS production, which induces stabilization of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and consequently promotes glycolysis. HIF-1 alpha-induced changes in monocyte metabolism by SARSCoV-2 infection directly inhibit T cell response and reduce epithelial cell survival. Targeting HIF-1 alpha may have great therapeutic potential for the development of novel drugs to treat COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据